# Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

> **NCT03482752** · PHASE3 · TERMINATED · sponsor: **Savara Inc.** · enrollment: 60 (actual)

## Conditions studied

- Autoimmune Pulmonary Alveolar Proteinosis

## Interventions

- **DRUG:** Molgramostim

## Key facts

- **NCT ID:** NCT03482752
- **Lead sponsor:** Savara Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-16
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-01-14
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** SAV006-03 was initiated before the evaluation of the IMPALA study (NCT02702180) results. Considering these results and authority advice there would not be adequate efficacy and safety data from SAV006-03 and the study was terminated.
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03482752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03482752, "Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03482752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*